In the above analysis, the high-risk group demonstrated a worse prognosis and fewer levels of immune cell infiltration, had invasion-associated mutational signatures (e.g., TP53 mutations), and demonstrated low benefitability in tumor immunotherapy. Here, TP53 is linked to neoplasm.